Early-Stage Innovation Forum invites expressions of interest


The Early-Stage Innovation Forum (ESIF) is calling for expressions of interest from developers interested in pitching their innovation at the 2023 AusBiotech national conference in Brisbane.

The ESIF rapid-fire pitch competition provides presenters with the opportunity to pitch their early-stage innovation to a panel of expert judges for feedback, with the November 3 ESIF competition focusing on early-stage human therapeutic and enabling technology projects.

This exclusive opportunity offers early-stage projects and technologies the chance to gather feedback essential for commercialising early-stage projects and technologies from a panel of industry experts as well as corporate VCs and early-stage investors.

During a seven-minute presentation, presenters will be required to outline the problem they are trying to address, their innovative approach to solving the problem, the technology’s competitive advantage, development plan and investment proposal. Submissions are open to investible projects from Australian research institutions or companies seeking seed or series A investment.

Companies that have advanced past seed and series A investment are encouraged to submit their expression of interest to present at Australia’s premier life science investment conference, AusBioInvest, in Melbourne on October 30.

The Forum is run bi-annually and, together, features presentations from Australia's local research institutes, universities, hospitals, and pre-series A companies, in the areas of human therapeutics, enabling technologies, medical devices, diagnostics, and digital health.

QIMR Berghofer’s A/Prof Michelle Hill, winner of Best Translational Research at the AusMedtech 2023 ESIF, said: “The feedback from the panel will help to further refine the pitch as I will be looking for investors for my startup to commercialise the discovered biomarkers to new blood tests for ovarian cancer diagnosis and early detection.”

Hear more about A/Prof Hill’s presentation on a novel ovarian cancer diagnostic tool here, and read about AusBiotech 2022 ESIF winners, Dr Melissa Knight (QIMR Berghofer) and Jonathan Bernadini (WEHI), here.

To register your project or company to present at the ESIF, with the conference website.

Submissions received by 8 September will be reviewed by the appointed Advisory Group and applicants will be contacted with further information once the evaluation process is complete on or before 22 September 2023.